A rapid and reliable test for BRCA1 and BRCA2 founder mutation analysis in paraffin tissue using pyrosequencing

Area of Science:

• Genetics
• Molecular Biology
• Oncology

Background:

• Founder mutations in BRCA1 and BRCA2 genes are prevalent in Ashkenazi Jewish populations, significantly increasing breast and ovarian cancer risk.
• Accurate identification of these specific BRCA mutations is crucial for effective clinical management of high-risk families.

Purpose of the Study:

• To develop and validate a rapid, reliable method for detecting common BRCA founder mutations.
• To assess the utility of pyrosequencing for analyzing DNA from diverse sample types, including challenging paraffin-embedded tissues.

Main Methods:

• Development of a pyrosequencing assay for detecting three specific BRCA founder mutations (BRCA1*185delAG, BRCA1*5382insC, BRCA2*6174delT).
• Validation using a blinded analysis of 177 DNA samples from paraffin tissues, blood, and saliva.
• Evaluation of assay accuracy, precision, and reliability across different specimen types.

Main Results:

• The pyrosequencing assay achieved 100% mutation detection rate with no false positives or negatives across all tested DNA samples.
• The method demonstrated high accuracy and precision, particularly for DNA extracted from paraffin-embedded tissues.
• Saliva proved to be a viable, non-invasive source for DNA isolation.

Conclusions:

• Pyrosequencing is a rapid, reliable, and accurate method for analyzing BRCA founder mutations, especially when paraffin-embedded tissues are the primary sample source.
• This approach facilitates the identification of high-risk individuals for targeted cancer management.
• The study highlights the potential of pyrosequencing for routine clinical diagnostics and research involving BRCA mutations.